{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:04:49Z","timestamp":1777907089488,"version":"3.51.4"},"reference-count":62,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["948\/19"],"award-info":[{"award-number":["948\/19"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Israel minstry of science","award":["66257"],"award-info":[{"award-number":["66257"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The etiological agent of the COVID-19 pandemic is SARS-CoV-2. As a member of the Coronaviridae, the enveloped pathogen has several membrane proteins, of which two, E and 3a, were suggested to function as ion channels. In an effort to increase our treatment options, alongside providing new research tools, we have sought to inhibit the 3a channel by targeted drug repurposing. To that end, using three bacteria-based assays, we screened a library of 2839 approved-for-human-use drugs and identified the following potential channel-blockers: Capreomycin, Pentamidine, Spectinomycin, Kasugamycin, Plerixafor, Flumatinib, Litronesib, Darapladib, Floxuridine and Fludarabine. The stage is now set for examining the activity of these compounds in detailed electrophysiological studies and their impact on the whole virus with appropriate biosafety measures.<\/jats:p>","DOI":"10.3390\/v13030532","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T23:59:41Z","timestamp":1616543981000},"page":"532","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5729-7066","authenticated-orcid":false,"given":"Prabhat Pratap Singh","family":"Tomar","sequence":"first","affiliation":[{"name":"Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Edmond J. Safra Campus Givat-Ram, Jerusalem 91904, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Krugliak","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Edmond J. Safra Campus Givat-Ram, Jerusalem 91904, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7659-1746","authenticated-orcid":false,"given":"Isaiah T.","family":"Arkin","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Edmond J. Safra Campus Givat-Ram, Jerusalem 91904, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","unstructured":"(Economist, 2020). Which economies are most vulnerable to covid-19\u2019s long-term effects?, Economist."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Perry, B.L., Aronson, B., and Pescosolido, B.A. (2021). Pandemic precarity: COVID-19 is exposing and exacerbating inequalities in the American heartland. Proc. Natl. Acad. Sci. USA, 118.","DOI":"10.1073\/pnas.2020685118"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., Hu, Y., Tao, Z.W., Tian, J.H., and Pei, Y.Y. (2020). A new coronavirus associated with human respiratory disease in China. Nature.","DOI":"10.1038\/s41586-020-2202-3"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1126\/science.1085953","article-title":"The Genome sequence of the SARS-associated coronavirus","volume":"300","author":"Marra","year":"2003","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1085952","article-title":"Characterization of a novel coronavirus associated with severe acute respiratory syndrome","volume":"300","author":"Rota","year":"2003","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(20)30557-2","article-title":"SARS-CoV-2 is an appropriate name for the new coronavirus","volume":"395","author":"Wu","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 - Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Simonovich, V.A., Burgos Pratx, L.D., Scibona, P., Beruto, M.V., Vallone, M.G., V\u00e1zquez, C., Savoy, N., Giunta, D.H., P\u00e9rez, L.G., and S\u00e1nchez, M.D.L. (2020). A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2031304"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Libster, R., P\u00e9rez Marc, G., Wappner, D., Coviello, S., Bianchi, A., Braem, V., Esteban, I., Caballero, M.T., Wood, C., and Berrueta, M. (2021). Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2033700"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1056\/NEJMp2009457","article-title":"Drug Evaluation during the Covid-19 Pandemic","volume":"382","author":"Rome","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in Patients Hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","unstructured":"RECOVERY Collaborative Group, Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., and Ustianowski, A. (2020). Dexamethasone in Hospitalized Patients with Covid-19\u2014Preliminary Report. N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"WHO Solidarity Trial Consortium, Pan, H., Peto, R., Henao-Restrepo, A.M., Preziosi, M.P., Sathiyamoorthy, V., Abdool Karim, Q., Alejandria, M.M., Hern\u00e1ndez Garc\u00eda, C., and Kieny, M.P. (2020). Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N. Engl. J. Med.","DOI":"10.1101\/2020.10.15.20209817"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"m4457","DOI":"10.1136\/bmj.m4457","article-title":"Covid-19: What now for remdesivir?","volume":"371","author":"Hsu","year":"2020","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zheng, J., and Trudeau, M.C. (2015). Handbook of Ion Channels, CRC Press.","DOI":"10.1201\/b18027"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0014-5793(03)00780-4","article-title":"Viroporins","volume":"552","author":"Gonzalez","year":"2003","journal-title":"FEBS Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrmicro2820","article-title":"Viroporins: Structure and biological functions","volume":"10","author":"Nieva","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1099\/vir.0.000201","article-title":"Viroporins: Structure, function and potential as antiviral targets","volume":"96","author":"Scott","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1126\/science.144.3620.862","article-title":"Antiviral activity of 1-adamantanamine (amantadine)","volume":"144","author":"Davies","year":"1964","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00000441-196905000-00005","article-title":"Treatment of influenza. The therapeutic efficacy of rimantadine HC1 in a naturally occurring influenza A2 outbreak","volume":"257","author":"Rabinovich","year":"1969","journal-title":"Am. J. Med. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJM196909112811102","article-title":"Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man","volume":"281","author":"Wingfield","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/j.1460-2075.1985.tb04038.x","article-title":"The molecular basis of the specific anti-influenza action of amantadine","volume":"4","author":"Hay","year":"1985","journal-title":"EMBO J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0092-8674(92)90452-I","article-title":"Influenza Virus M2 Protein Has Ion Channel Activity","volume":"69","author":"Pinto","year":"1992","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0140-6736(05)67340-0","article-title":"Resistance to anti-influenza agents","volume":"366","author":"Guan","year":"2005","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Casta\u00f1o-Rodriguez, C., Honrubia, J.M., Guti\u00e9rrez-\u00c1lvarez, J., DeDiego, M.L., Nieto-Torres, J.L., Jimenez-Guarde\u00f1o, J.M., Regla-Nava, J.A., Fernandez-Delgado, R., Verdia-B\u00e1guena, C., and Queralt-Mart\u00edn, M. (2018). Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis. mBio, 9.","DOI":"10.1128\/mBio.02325-17"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"573339","DOI":"10.3389\/fimmu.2020.573339","article-title":"Coronavirus Proteins as Ion Channels: Current and Potential Research","volume":"11","author":"McClenaghan","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbrc.2020.05.206","article-title":"SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine","volume":"530","author":"Arkin","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.virol.2004.09.033","article-title":"SARS coronavirus E protein forms cation-selective ion channels","volume":"330","author":"Wilson","year":"2004","journal-title":"Virology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.virol.2006.05.028","article-title":"Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication","volume":"353","author":"Wilson","year":"2006","journal-title":"Virology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1128\/JVI.01472-06","article-title":"Role of the coronavirus E viroporin protein transmembrane domain in virus assembly","volume":"81","author":"Ye","year":"2007","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1110\/ps.062730007","article-title":"Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein","volume":"16","author":"Torres","year":"2007","journal-title":"Protein Sci."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Pervushin, K., Tan, E., Parthasarathy, K., Lin, X., Jiang, F.L., Yu, D., Vararattanavech, A., Soong, T.W., Liu, D.X., and Torres, J. (2009). Structure and inhibition of the SARS coronavirus envelope protein ion channel. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000511"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.virol.2012.07.005","article-title":"Coronavirus E protein forms ion channels with functionally and structurally-involved membrane lipids","volume":"432","author":"Alcaraz","year":"2012","journal-title":"Virology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.bbamem.2013.05.008","article-title":"Analysis of SARS-CoV E protein ion channel activity by tuning the protein and lipid charge","volume":"1828","author":"Alcaraz","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Nieto-Torres, J.L., DeDiego, M.L., Verdi\u00e1-B\u00e1guena, C., Jimenez-Guarde\u00f1o, J.M., Regla-Nava, J.A., Fernandez-Delgado, R., Casta\u00f1o-Rodriguez, C., Alcaraz, A., Torres, J., and Aguilella, V.M. (2014). Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004077"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.virusres.2015.02.023","article-title":"MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels","volume":"201","author":"Surya","year":"2015","journal-title":"Virus Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.virol.2015.08.010","article-title":"Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome","volume":"485","author":"Torres","year":"2015","journal-title":"Virology"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"To, J., Surya, W., Fung, T.S., Li, Y., Verdi\u00e0-B\u00e0guena, C., Queralt-Martin, M., Aguilella, V.M., Liu, D.X., and Torres, J. (2017). Channel-Inactivating Mutations and Their Revertant Mutants in the Envelope Protein of Infectious Bronchitis Virus. J. Virol., 91.","DOI":"10.1128\/JVI.02158-16"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Westerbeck, J.W., and Machamer, C.E. (2019). The Infectious Bronchitis Coronavirus Envelope Protein Alters Golgi pH To Protect the Spike Protein and Promote the Release of Infectious Virus. J. Virol., 93.","DOI":"10.1128\/JVI.00015-19"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.3389\/fmicb.2019.03022","article-title":"Regulation of the ER Stress Response by the Ion Channel Activity of the Infectious Bronchitis Coronavirus Envelope Protein Modulates Virion Release, Apoptosis, Viral Fitness, and Pathogenesis","volume":"10","author":"Li","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"12540","DOI":"10.1073\/pnas.0605402103","article-title":"Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release","volume":"103","author":"Lu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.biocel.2009.04.019","article-title":"The ion channel activity of the SARS-coronavirus 3a protein is linked to its pro-apoptotic function","volume":"41","author":"Chan","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2011.02.008","article-title":"Emodin inhibits current through SARS-associated coronavirus 3a protein","volume":"90","author":"Schwarz","year":"2011","journal-title":"Antiviral. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1016\/j.jmb.2016.08.007","article-title":"Mapping the Resistance Potential of Influenza\u2019s H+ Channel against an Antiviral Blocker","volume":"428","author":"Assa","year":"2016","journal-title":"J. Mol. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Singh Tomar, P.P., Krugliak, M., and Arkin, I.T. (2021). Targeted Drug Repurposing against the SARS-CoV-2 E Channel Identifies Blockers with Antiviral Activity. bioRxiv.","DOI":"10.1101\/2021.02.24.432490"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Tomar, P.P.S., Oren, R., Krugliak, M., and Arkin, I.T. (2019). Potential Viroporin Candidates From Pathogenic Viruses Using Bacteria-Based Bioassays. Viruses, 11.","DOI":"10.3390\/v11070632"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s002030050425","article-title":"Requirement of a Large K+-Uptake Capacity and of Extracytoplasmic Protease Activity for Protamine Resistance of Escherichia Coli","volume":"167","author":"Stumpe","year":"1997","journal-title":"Arch. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.bbamem.2010.08.021","article-title":"Quantitative analysis of influenza M2 channel blockers","volume":"1808","author":"Astrahan","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Taube, R., Alhadeff, R., Assa, D., Krugliak, M., and Arkin, I.T. (2014). Bacteria-based analysis of HIV-1 Vpu channel activity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105387"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/28190","article-title":"Visualizing Secretion and Synaptic Transmission with pH-Sensitive Green Fluorescent Proteins","volume":"394","author":"Rothman","year":"1998","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","volume":"586","author":"Riva","year":"2020","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1021\/acs.biochem.8b00722","article-title":"Random Mutagenesis Analysis of the Influenza A M2 Proton Channel Reveals Novel Resistance Mutants","volume":"57","author":"Santner","year":"2018","journal-title":"Biochemistry"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1021\/acs.biochem.8b00721","article-title":"A Robust Proton Flux (pHlux) Assay for Studying the Function and Inhibition of the Influenza A M2 Proton Channel","volume":"57","author":"Santner","year":"2018","journal-title":"Biochemistry"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/3\/532\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:40:01Z","timestamp":1760161201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/3\/532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":62,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["v13030532"],"URL":"https:\/\/doi.org\/10.3390\/v13030532","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]}}}